We are proud to announce today our Euro 25 million financing round led by TVM Capital Life Science in cooperation with DPE Deutsche Private Equity, Careventures and CIC Capital. Currently we are now already providing the largest test portfolio for rare genetic diagnostics worldwide with testing samples from over 110 different countries, allowing us to generate unique insights into the epidemiological basis of hereditary disorders and the link between genotypic and phenotypic data. “There is a large unmet need for diagnosis and treatment of rare diseases – 80% of which have genetic causes”, comments Prof. Arndt Rolfs, MD, CEO and Founder of CENTOGENE GmbH. We aim to intensify our focus on developing biomarkers, companion diagnostics and oncogenetics, and further accelerate our growth into personalized medicine with innovation.